WO2007030571A3 - Identification of targets and development of reagents for testing and molecular imaging of human disease - Google Patents
Identification of targets and development of reagents for testing and molecular imaging of human disease Download PDFInfo
- Publication number
- WO2007030571A3 WO2007030571A3 PCT/US2006/034777 US2006034777W WO2007030571A3 WO 2007030571 A3 WO2007030571 A3 WO 2007030571A3 US 2006034777 W US2006034777 W US 2006034777W WO 2007030571 A3 WO2007030571 A3 WO 2007030571A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reagents
- identification
- development
- targets
- imaging
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention describes both the identification of disease target molecules and the development of imaging reagents and diagnostic assays specific to those molecules. Described herein are methods and reagents for the identification of molecular targets specific to a disease or disease state, methods of imaging technology which can be used, the development of specific molecular imaging reagents, clinical validation of the imaging reagents, and clinical indications for molecular imaging.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71479005P | 2005-09-06 | 2005-09-06 | |
US60/714,790 | 2005-09-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007030571A2 WO2007030571A2 (en) | 2007-03-15 |
WO2007030571A3 true WO2007030571A3 (en) | 2007-08-30 |
Family
ID=37836417
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/034777 WO2007030571A2 (en) | 2005-09-06 | 2006-09-06 | Identification of targets and development of reagents for testing and molecular imaging of human disease |
PCT/US2006/034703 WO2007030531A2 (en) | 2005-09-06 | 2006-09-06 | Reagents for testing and molecular imaging of liver cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/034703 WO2007030531A2 (en) | 2005-09-06 | 2006-09-06 | Reagents for testing and molecular imaging of liver cancer |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2007030571A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008014404A2 (en) | 2006-07-26 | 2008-01-31 | The University Of Chicago | Receptor-mediated delivery : compositions and methods |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
CA2717854C (en) | 2008-03-03 | 2019-02-19 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
DE102008039417A1 (en) | 2008-08-13 | 2010-02-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Agent for the detection and treatment of prostate cells |
US8735082B2 (en) | 2008-11-10 | 2014-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
US20120190049A1 (en) * | 2010-12-10 | 2012-07-26 | University Of Washington Through Its Center For Commercialization | Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles |
US8900822B2 (en) | 2011-11-21 | 2014-12-02 | Ethicon, Inc. | Fibrinogen assay |
WO2013148147A1 (en) | 2012-03-26 | 2013-10-03 | The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
KR102357173B1 (en) | 2013-10-11 | 2022-01-27 | 옥스포드 바이오테라퓨틱스 리미티드 | Conjugated antibodies against ly75 for the treatment of cancer |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
CN107328746B (en) * | 2017-06-14 | 2020-01-31 | 宁波大学 | Preparation and application of multifunctional fluorescent biosensors based on nucleic acid-like coordination polymers |
CN111273010B (en) * | 2018-12-04 | 2023-04-18 | 北京蛋白质组研究中心 | Application of kit for detecting SOAT1 protein expression level in preparation of hepatocellular carcinoma screening product |
US20200191785A1 (en) * | 2018-12-18 | 2020-06-18 | Euroimmun Medizinische Labordiagnostika Ag | Method for Diagnosing Autoimmune Gastritis |
CN109701039A (en) * | 2019-01-17 | 2019-05-03 | 浙江大学 | A kind of preparation method of liver cancer dual-target magnetic nanoparticle |
CN109897900B (en) * | 2019-03-13 | 2023-04-07 | 温州医科大学 | Application of EPB42 gene in liver cancer SBRT curative effect evaluation |
WO2020251306A1 (en) * | 2019-06-14 | 2020-12-17 | Seegene, Inc. | Computer-implemented method for collaborative development of reagents for detection of target nucleic acids |
CN115166245A (en) * | 2021-04-04 | 2022-10-11 | 兰州大学第一医院 | Application of CLU and its composition in the diagnosis of cholangiocarcinoma and diagnostic kit for cholangiocarcinoma |
CN113249476B (en) * | 2021-05-12 | 2022-10-14 | 复旦大学 | Key protein BLT2 influencing tumor cell dryness and application thereof |
CN113151482A (en) * | 2021-05-21 | 2021-07-23 | 深圳泰莱生物科技有限公司 | Method for identifying benign and malignant lung nodules based on monochromatic multiple fluorescence quantitative PCR |
CN117647645B (en) * | 2024-01-29 | 2024-04-12 | 中国人民解放军总医院第一医学中心 | Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit |
CN118471472B (en) * | 2024-05-22 | 2025-07-22 | 中国人民解放军海军军医大学第三附属医院 | Marker, kit, system and application for screening or diagnosing early liver cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
US20020081640A1 (en) * | 2000-06-28 | 2002-06-27 | Macina Roberto A. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
US20020122806A1 (en) * | 2001-03-05 | 2002-09-05 | Chinnaiyan Arul M. | Compositions and methods for in situ and in vivo imaging of cells and tissues |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20050130167A1 (en) * | 2002-10-25 | 2005-06-16 | Gang Bao | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
US20050192458A1 (en) * | 2002-04-30 | 2005-09-01 | Goodman Mark M. | Tumor imaging compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042386A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
-
2006
- 2006-09-06 WO PCT/US2006/034777 patent/WO2007030571A2/en active Application Filing
- 2006-09-06 WO PCT/US2006/034703 patent/WO2007030531A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
US20020081640A1 (en) * | 2000-06-28 | 2002-06-27 | Macina Roberto A. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
US20020122806A1 (en) * | 2001-03-05 | 2002-09-05 | Chinnaiyan Arul M. | Compositions and methods for in situ and in vivo imaging of cells and tissues |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20050192458A1 (en) * | 2002-04-30 | 2005-09-01 | Goodman Mark M. | Tumor imaging compounds |
US20050130167A1 (en) * | 2002-10-25 | 2005-06-16 | Gang Bao | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
Also Published As
Publication number | Publication date |
---|---|
WO2007030531A3 (en) | 2007-11-15 |
WO2007030571A2 (en) | 2007-03-15 |
WO2007030531A2 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007030571A3 (en) | Identification of targets and development of reagents for testing and molecular imaging of human disease | |
WO2007079284A3 (en) | Lung cancer diagnostic assay | |
WO2008039769A3 (en) | Methods and devices for analyzing small rna molecules | |
WO2006079049A3 (en) | Methods and compositions for increased dynamic range detection of nucleic acid molecules | |
WO2006128042A3 (en) | Methods of identifying mutations in nucleic acid | |
WO2008070865A3 (en) | Materials and methods for efficient and accurate detection of analytes | |
WO2007114986A3 (en) | Cooperative probes and methods of using them | |
WO2006020269A3 (en) | Biomarkers of neurodegenerative disease | |
WO2008048230A3 (en) | Methods of identifying biological targets and instrumentation to identify biological targets | |
EP2021512A4 (en) | Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets | |
WO2007008276A3 (en) | Turnover probes and use thereof for nucleic acid detection | |
WO2010027903A8 (en) | Lung cancer diagnosis | |
WO2007133682A3 (en) | 100% sequence identity detection methods for variable genomes | |
WO2008008708A3 (en) | Lung cancer diagnostic assay | |
WO2004092734A3 (en) | Novel approach to molecular diagnosis of human papilloma virus-related diseases | |
EP2535718A3 (en) | Methods for early diagnosis of kidney disease | |
WO2007119179A3 (en) | Use of the ornithine transcarbamylase (otc), as a marker for diagnosing brain damages | |
WO2008019052A3 (en) | Methods and compositions for identifying biomarkers | |
WO2006099543A3 (en) | Methods for assessing antibody-mediated cytotoxicity | |
WO2007132120A3 (en) | Procedure and methods for detecting alzheimer's disease | |
WO2008124091A3 (en) | Compositions and methods of detection | |
WO2008131261A3 (en) | Peptide biomarkers of cardiovascular disease | |
WO2008108873A3 (en) | Molecular biosensors for detecting macromolecules and other analytes | |
WO2007020522A3 (en) | Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type | |
WO2002092858A3 (en) | Methods of screening for disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06814248 Country of ref document: EP Kind code of ref document: A2 |